Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Journal of gastrointestinal oncology
View this publicationJournal of gastrointestinal oncology
View this publicationThe Journal of infectious diseases
View this publicationBMC nephrology
View this publicationJHEP reports : innovation in hepatology
View this publicationBMC infectious diseases
View this publicationPathogens (Basel, Switzerland)
View this publicationCell reports
View this publicationUnited European gastroenterology journal
View this publicationInternational journal of molecular sciences
View this publicationClinical transplantation
View this publication